CMRX - Chimerix, Inc.
| Previous close | 1.4500 |
| Open | 1.4600 |
| Bid | 1.4200 x 900 |
| Ask | 1.4300 x 3200 |
| Day's range | 1.4000 - 1.4600 |
| 52-week range | 1.0900 - 2.9000 |
| Volume | |
| Avg. volume | 934,361 |
| Market cap | 125.789M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | 0.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
Chimerix First Quarter 2023 Earnings: Beats Expectations
Chimerix ( NASDAQ:CMRX ) First Quarter 2023 Results Key Financial Results Revenue: US$283.0k (up by US$268.0k from 1Q...
- Zacks
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Chimerix (CMRX) Loses -24.68% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Chimerix (CMRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- Simply Wall St.
With 53% ownership of the shares, Chimerix, Inc. (NASDAQ:CMRX) is heavily dominated by institutional owners
Every investor in Chimerix, Inc. ( NASDAQ:CMRX ) should be aware of the most powerful shareholder groups. We can see...
- Zacks
Chimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?
Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- Zacks
Zacks.com featured highlights Chimerix, Vista Oil & Gas and Arcus Biosciences
Chimerix, Vista Oil & Gas and Arcus Biosciences have been highlighted in this Screen of The Week article.
- Zacks
Buy 3 of the Best Stocks by Using Net Income Ratio
Chimerix (CMRX), Vista Oil & Gas (VIST) and Arcus Biosciences (RCUS) have been selected as the top picks with a high net income ratio.
- Zacks
Chimerix (CMRX) Beats Q3 Earnings Estimates
Chimerix (CMRX) delivered earnings and revenue surprises of 30.95% and 84.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Perrigo (PRGO) Earnings Expected to Grow: Should You Buy?
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Chimerix (CMRX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
- Zacks
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
- Simply Wall St.
Institutional investors own a significant stake of 49% in Chimerix, Inc. (NASDAQ:CMRX)
A look at the shareholders of Chimerix, Inc. ( NASDAQ:CMRX ) can tell us which group is most powerful. We can see that...
- Zacks
Implied Volatility Surging for Chimerix (CMRX) Stock Options
Investors need to pay close attention to Chimerix (CMRX) stock based on the movements in the options market lately.
- Motley Fool
Chimerix (CMRX) Q2 2022 Earnings Call Transcript
With me on today's call are president and chief executive officer, Mike Sherman; chief medical officer, Allen Melemed; chief financial and business officer, Mike Andriole; chief science officer, Randall Lanier; and our chief technology officer of Imipridones, Josh Allen. Before we begin, I'd like to remind you that the statements made on today's call include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties and other factors.
- Yahoo Finance Video
WHO declares Monkeypox a global health emergency
Yahoo Finance Live anchors report that WHO has declared Monkeypox a global health emergency.
- Simply Wall St.
Is Chimerix (NASDAQ:CMRX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Simply Wall St.
Insiders who bought stock earlier this year lose -US$93k as Chimerix, Inc. (NASDAQ:CMRX) drops to US$120m
The recent price decline of 24% in Chimerix, Inc.'s ( NASDAQ:CMRX ) stock may have disappointed insiders who bought...
